TY  - JOUR
  - Review Articles
  - Murphy, CT,Nally, K,Shanahan, F,Melgar, S
  - 2012
  - January
  - Shining a Light on Intestinal Traffic
  - Validated
  - 1
  - ()
  - INFLAMMATORY-BOWEL-DISEASE CELL-ADHESION MOLECULE-1 ACTIVE CROHNS-DISEASE MURINE EXPERIMENTAL COLITIS RENAL-TRANSPLANT PATIENTS EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS SPHINGOSINE 1-PHOSPHATE RECEPTORS RELAPSING MULTIPLE-SCLEROSIS SECONDARY LYMPHOID ORGANS CD103(+) DENDRITIC CELLS
  - Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is associated with enhanced leukocyte infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte trafficking is a major target for IBD therapy. Past and emerging techniques to study leukocyte trafficking both in vitro and in vivo have expanded our knowledge of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there is an abundance of preclinical data demonstrating efficacy of leukocyte trafficking inhibitors, many have yet to be confirmed in clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.
  - ARTN 808157
DA  - 2012/01
ER  - 

@article{V160956855,
   = {Review Articles},
   = {Murphy,  CT and Nally,  K and Shanahan,  F and Melgar,  S },
   = {2012},
   = {January},
   = {Shining a Light on Intestinal Traffic},
   = {Validated},
   = {1},
   = {()},
   = {INFLAMMATORY-BOWEL-DISEASE CELL-ADHESION MOLECULE-1 ACTIVE CROHNS-DISEASE MURINE EXPERIMENTAL COLITIS RENAL-TRANSPLANT PATIENTS EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS SPHINGOSINE 1-PHOSPHATE RECEPTORS RELAPSING MULTIPLE-SCLEROSIS SECONDARY LYMPHOID ORGANS CD103(+) DENDRITIC CELLS},
   = {{Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is associated with enhanced leukocyte infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte trafficking is a major target for IBD therapy. Past and emerging techniques to study leukocyte trafficking both in vitro and in vivo have expanded our knowledge of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there is an abundance of preclinical data demonstrating efficacy of leukocyte trafficking inhibitors, many have yet to be confirmed in clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.}},
   = {ARTN 808157},
  source = {IRIS}
}